In 2015, a post hoc exploratory analysis of subjects enrolled in the PANTHER-IPF clinical trial was conducted to determine whether specific polymorphisms in toll-interacting protein (TOLLIP) and MUC5B genes modified the efficacy of NAC. This evidence concerns the gene TOLLIP and idiopathic pulmonary fibrosis.